Ketamine Infusions Reduce Depression Severity in Treatment-Resistant Bipolar Disorder
A randomized, double-blind trial (Ket-BD) compared four IV ketamine infusions with midazolam, added to a stable mood stabilizer or antipsychotic, in adults with treatment-resistant bipolar I or II depression. The trial reported a significantly greater reduction in MADRS depression scores with ketamine versus midazolam at day 14, with no cases of mania, hypomania, psychosis, or suicide attempts in either group, and one case of subthreshold mixed features in each arm.
Most relevant for: Adults with treatment-resistant bipolar I or II depression who have not responded to at least two prior evidence-based pharmacotherapies.
Read the original at JAMA PsychiatrySummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More psychiatry updates
- Caring Letters Not Linked to Lower Suicide Mortality in VeteransOct 14, 2026
- US benzodiazepine dispensing fell 26.7% from 2013 to 2024Sep 30, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 1 mL, Delivers: 10 mL, Oral Elixir, PAI, Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 5 mg per 10 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026
- Class II recall: Safecor Health, LLC: Fluphenazine HCl Elixir, USP, 10 mg per 2 mL, Delivers: 10 mL, Oral Elixir, PAI,Sep 23, 2026